Merck & Co., Inc. news

   Watch this stock
Showing stories 1 - 10 of about 158   

Articles published

MRK 55.13 +1.08 (2.00%)
price chart
A Quick Look at Merck & Co. Inc.'s Drug Development Pipeline
Today, I'd suggest we take a closer look at Merck's (NYSE: MRK ) drug development pipeline in order to get a better idea of how well the company is preparing for its future beyond patent expirations, as well as note which handful of developing drugs ...
Related articles »  
Bayer closes acquisition of consumer care business of Merck & Co., Inc. for ...
Bayer has completed the global acquisition of the consumer care business of the U.S. pharmaceuticals group Merck & Co., Inc., Whitehouse Station, New Jersey. The transaction closed on October 1, 2014, following receipt of required antitrust approvals.
Company Update: Merck & Co Inc (NYSE:MRK) - Merck Completes Sale of ...  Jutia Group
Related articles »  
Better Dividend Stock: Merck & Co. Inc. or Bristol-Myers Squibb Co.?
Dividend stocks are arguably the most critical component to the success of any long-term investor. According to the latest statistics from FactSet, S&P 500 companies paid out a whopping $91.5 billion in dividends during the second quarter, or an ...
Related articles »  
Higher gross margins are more profitable: Merck & Co., Inc. (MRK), Edison ...
Merck & Co., Inc. (NYSE:MRK) has return on equity ratio of 11.50%. The company has $155.91 billion in market worth. Gross Profit margin is maintained at 60.20%.
Related articles »  
Ex-Merck analyst faces insider trading charges on merger tips
NEW YORK Oct 14 (Reuters) - Federal prosecutors in New York charged a former Merck & Co Inc employee with conspiracy to commit fraud for tipping a contact about potential mergers, including Merck's takeover of Idenix Pharmaceuticals ahead of a public ...
Company Update (NYSE:MRK): Ex-Merck analyst faces insider trading charges ...  Jutia Group
Ex-Merck Analyst Charged With Telling Friend of Buyout  Bloomberg
Related articles »  
Merck Still Looks Very Expensive (MRK)
Oct. 14, 2014 3:02 PM ET | About: Merck & Co Inc. (MRK) by: Stock Traders Daily ... Earnings growth was dismal prior to the recent quarter, but because the comps from the second quarter of 2012 were no longer in the equation the trailing 12 month ...
Valuation analysis for Merck & Co., Inc. (NYSE:MRK)  Stock Traders Daily
Related articles »  
Ragwitek by Merck & Co, Inc, and Catalent Pharma
The FDA has approved sublingual Ragwitek (Short Ragweed Pollen Allergen Extract) tablets as an immunotherapy option for selected patients with confirmed ragweed pollen�induced allergic rhinitis.
Related articles »  
MOST ACTIVE HEALTH CARE: Merck & Co., Inc. (NYSE:MRK), Johnson ...
Swiss drug manufacturer Roche and U.S. group Merck & Co., Inc. (NYSE:MRK) are going to present data on their competingimmune-therapy medicines in breast cancer in December, spreading the novel tactic to fighting tumor's to another cancer type.
Related articles »  
Merck & Co., Inc. (MRK), The Walt Disney Company (DIS), The Boeing Company ...
Abner Herrman & Brock owns 265,643 shares of Merck & Co., Inc. (NYSE:MRK) with net market value of $15.7 million. The drug manufacturer sold its consumer care unit, Merck Consumer Care, for $14.2 billion to Bayer AG.
Merck & Co., Inc. Stock Still Holding Its Position As A Big-Pharma Leader
Merck & Co. (NYSE: MRK) is the perfect example of a go-to �safe harbor� stock when market conditions turn bearish, as they did last Thursday and early Monday morning.
Related articles »